1. Home
  2. STK vs ALT Comparison

STK vs ALT Comparison

Compare STK & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STK
  • ALT
  • Stock Information
  • Founded
  • STK 2009
  • ALT 1997
  • Country
  • STK United States
  • ALT United States
  • Employees
  • STK N/A
  • ALT N/A
  • Industry
  • STK Investment Managers
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • STK Finance
  • ALT Health Care
  • Exchange
  • STK Nasdaq
  • ALT Nasdaq
  • Market Cap
  • STK 545.8M
  • ALT 472.3M
  • IPO Year
  • STK N/A
  • ALT N/A
  • Fundamental
  • Price
  • STK $26.57
  • ALT $4.97
  • Analyst Decision
  • STK
  • ALT Strong Buy
  • Analyst Count
  • STK 0
  • ALT 8
  • Target Price
  • STK N/A
  • ALT $21.00
  • AVG Volume (30 Days)
  • STK 38.2K
  • ALT 2.2M
  • Earning Date
  • STK 01-01-0001
  • ALT 05-08-2025
  • Dividend Yield
  • STK 6.60%
  • ALT N/A
  • EPS Growth
  • STK N/A
  • ALT N/A
  • EPS
  • STK N/A
  • ALT N/A
  • Revenue
  • STK N/A
  • ALT $20,000.00
  • Revenue This Year
  • STK N/A
  • ALT N/A
  • Revenue Next Year
  • STK N/A
  • ALT N/A
  • P/E Ratio
  • STK N/A
  • ALT N/A
  • Revenue Growth
  • STK N/A
  • ALT N/A
  • 52 Week Low
  • STK $24.95
  • ALT $3.55
  • 52 Week High
  • STK $34.31
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • STK 45.62
  • ALT 52.93
  • Support Level
  • STK $25.04
  • ALT $4.32
  • Resistance Level
  • STK $26.86
  • ALT $4.75
  • Average True Range (ATR)
  • STK 1.14
  • ALT 0.37
  • MACD
  • STK 0.09
  • ALT 0.12
  • Stochastic Oscillator
  • STK 79.78
  • ALT 95.02

About STK Columbia Seligman Premium Technology Growth Fund Inc

Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Share on Social Networks: